Azienda Ospedaliera S. Andrea - Università La Sapienza
About Azienda Ospedaliera S. Andrea - Università La Sapienza
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Celgene
5
Hoffmann-La Roche
3
Janssen Research & Development, LLC
3
Ferring Pharmaceuticals
2
Amgen
1
Geron Corporation
1
Janssen-Cilag Ltd.
1
MacroGenics
1
MedDay Pharmaceuticals SA
1
Merck KGaA, Darmstadt, Germany
1
Clinical Trials at Azienda Ospedaliera S. Andrea - Università La Sapienza
During the past decade, Azienda Ospedaliera S. Andrea - Università La Sapienza conducted 14 clinical trials. In the 10-year time frame, 14 clinical trials started and 8 clinical trials were completed, i.e. on
average, 57.1% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 7 clinical trials were completed. i.e. 233.3%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients
2009-08-01
2011-03-01
Completed
182
A Long Term Safety Study of Degarelix in Patients With Prostate Cancer
2009-08-01
2011-12-01
Completed
77
Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission
2013-04-24
2023-12-31
Active, not recruiting
472
Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)
2013-11-21
2022-01-26
Completed
358
Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)
2014-02-20
2021-12-23
Completed
85
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
2015-08-24
2022-06-14
Completed
624
Study to Evaluate Imetelstat (GRN163L) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
2015-11-24
2026-10-13
Recruiting
278
A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy
2016-06-03
2024-10-31
Active, not recruiting
130
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Azienda Ospedaliera S. Andrea - Università La Sapienza" #1 sponsor was "Celgene" with 5 trials, followed by "Hoffmann-La Roche" with 3 trials
sponsored, "Janssen Research & Development, LLC" with 3 trials sponsored, "Ferring Pharmaceuticals" with 2 trials sponsored and "Amgen"
with 2 trials sponsored. Other sponsors include 0 different institutions and
companies that sponsored additional 10 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Azienda Ospedaliera S. Andrea - Università La Sapienza"
#1 collaborator was "Chugai Pharmaceutical" with 1 trials as a collaborator, "Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation" with 1 trials as a collaborator and "Novartis" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were
collaborators in the rest 3 trials.
Clinical Trials Conditions at Azienda Ospedaliera S. Andrea - Università La Sapienza
According to Clinical.Site data, the most researched conditions in "Azienda Ospedaliera S. Andrea - Università La Sapienza" are
"Multiple Sclerosis" (3 trials), "Leukemia, Myeloid, Acute" (2 trials), "Prostate Cancer" (2 trials), "Schizophrenia" (2 trials) and "Depressive Disorder, Treatment-Resistant" (1 trials). Many other conditions were trialed in "Azienda Ospedaliera S. Andrea - Università La Sapienza" in a lesser frequency.
Clinical Trials Intervention Types at Azienda Ospedaliera S. Andrea - Università La Sapienza
Most popular intervention types in "Azienda Ospedaliera S. Andrea - Università La Sapienza" are "Drug" (18 trials), "Biological" (1 trials) and "Other" (1 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (6 trials), "Degarelix" (2 trials), "AG-120" (1 trials), "AG-221" (1 trials) and "AMG334" (1 trials). Other intervention names were less common.
Clinical Trials Genders at Azienda Ospedaliera S. Andrea - Università La Sapienza
The vast majority of trials in "Azienda Ospedaliera S. Andrea - Università La Sapienza" are
17 trials for "All" genders and 2 trials for "Male" genders.
Clinical Trials Status at Azienda Ospedaliera S. Andrea - Università La Sapienza
Currently, there are NaN active trials in "Azienda Ospedaliera S. Andrea - Università La Sapienza".
undefined are not yet recruiting,
4 are recruiting,
4 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 10 completed trials in Azienda Ospedaliera S. Andrea - Università La Sapienza,
undefined suspended trials,
and 1 terminated clinical trials to date.
Out of the total trials that were conducted in Azienda Ospedaliera S. Andrea - Università La Sapienza, 1 "Phase 1"
clinical trials were conducted, 2 "Phase 2" clinical
trials and 14 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 2 trials, and there were
also 0 trials that are defined as “Not Applicable".